- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Multispot laser system receives FDA clearance
The Vitra Multispot laser (Quantel Medical) has received a 510(k) market clearance from the FDA. It is intended to deliver a cost-effective solution to ophthalmologists dealing with epidemic levels of diabetic eye disease.
Clermont-Ferrand, France-The Vitra Multispot laser (Quantel Medical) has received a 510(k) market clearance from the FDA. The product was developed by Quantel Medical to give access to advanced pattern-scanning technology to ophthalmology practices worldwide though intelligent design.
The laser combines advanced pattern scanning and solid-state green laser technologies in a compact portable platform to deliver a cost-effective solution to ophthalmologists around the world dealing with epidemic levels of diabetic eye disease in their patient populations, according to the company.
“The [multispot laser] has accelerated our capability to manage the growing number of diabetic patients coming to our practice for care and [has] improved our reputation for superior patient care since the pattern-scanning laser treatment . . . is less painful compared [with] the previous treatments many patients received with a conventional laser,” said Rama D. Jager, MD, MBA, FACS of University Retina, Oak Forest, IL, who was the first user of the Vitra Multispot in the United States.
For more articles in this issue of Ophthalmology Times eReport, click here.
